IDH1 is altered in 2.96% of malignant solid tumor patients with IDH1 Mutation present in 2.84% of all malignant solid tumor patients [4].

IDH1 Mutation is an inclusion criterion in 10 clinical trials for malignant solid tumor, of which 8 are open and 2 are closed. Of the trials that contain IDH1 Mutation and malignant solid tumor as inclusion criteria, 5 are phase 1 (3 open) and 5 are phase 2 (5 open) [5].

IDH1 is altered in 7.58% of acute myeloid leukemia patients with IDH1 Mutation present in 7.58% of all acute myeloid leukemia patients [4].

IDH1 Mutation is an inclusion criterion in 9 clinical trials for acute myeloid leukemia, of which 7 are open and 2 are closed. Of the trials that contain IDH1 Mutation and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (1 open), 4 are phase 1/phase 2 (4 open), 2 are phase 2 (1 open), and 1 is phase 3 (1 open) [5].

IDH1 is altered in 24.88% of glioma patients with IDH1 Mutation present in 24.85% of all glioma patients [4].

IDH1 Mutation is an inclusion criterion in 8 clinical trials for glioma, of which 7 are open and 1 is closed. Of the trials that contain IDH1 Mutation and glioma as inclusion criteria, 3 are phase 1 (3 open), 4 are phase 2 (3 open), and 1 is no phase specified (1 open) [5].

IDH1 is altered in 19.88% of malignant glioma patients with IDH1 Mutation present in 19.85% of all malignant glioma patients [4].

IDH1 Mutation is an inclusion criterion in 4 clinical trials for malignant glioma, of which 4 are open and 0 are closed. Of the trials that contain IDH1 Mutation and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [5].

IDH1 is altered in 15.57% of cholangiocarcinoma patients with IDH1 Mutation present in 15.48% of all cholangiocarcinoma patients [4].

IDH1 Mutation is an inclusion criterion in 4 clinical trials for cholangiocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain IDH1 Mutation and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (1 open) [5].

IDH1 is altered in 57.88% of anaplastic astrocytoma patients with IDH1 Mutation present in 57.88% of all anaplastic astrocytoma patients [4].

IDH1 Mutation is an inclusion criterion in 3 clinical trials for anaplastic astrocytoma, of which 2 are open and 1 is closed. Of the trials that contain IDH1 Mutation and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 3 (1 open) [5].

IDH1 is altered in 0.57% of lymphoma patients with IDH1 Mutation present in 0.48% of all lymphoma patients [4].

IDH1 Mutation is an inclusion criterion in 3 clinical trials for lymphoma, of which 1 is open and 2 are closed. Of the trials that contain IDH1 Mutation and lymphoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 2 (1 open) [5].

IDH1 is altered in 0.45% of breast carcinoma patients with IDH1 Mutation present in 0.36% of all breast carcinoma patients [4].

IDH1 Mutation is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 1 is open and 2 are closed. Of the trials that contain IDH1 Mutation and breast carcinoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 2 (1 open) [5].

IDH1 is altered in 68.64% of WHO grade II glioma patients with IDH1 Mutation present in 68.64% of all WHO grade II glioma patients [4].

IDH1 Mutation is an inclusion criterion in 2 clinical trials for WHO grade II glioma, of which 2 are open and 0 are closed. Of the trials that contain IDH1 Mutation and WHO grade II glioma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [5].

IDH1 is altered in 59.02% of WHO grade III glioma patients with IDH1 Mutation present in 59.02% of all WHO grade III glioma patients [4].

IDH1 Mutation is an inclusion criterion in 2 clinical trials for WHO grade III glioma, of which 2 are open and 0 are closed. Of the trials that contain IDH1 Mutation and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [5].

IDH1 is altered in 22.3% of chondrosarcoma patients with IDH1 Mutation present in 22.3% of all chondrosarcoma patients [4].

IDH1 Mutation is an inclusion criterion in 2 clinical trials for chondrosarcoma, of which 2 are open and 0 are closed. Of the trials that contain IDH1 Mutation and chondrosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IDH1 is altered in 9.61% of glioblastoma patients with IDH1 Mutation present in 9.58% of all glioblastoma patients [4].

IDH1 Mutation is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain IDH1 Mutation and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) [5].

IDH1 is altered in 2.52% of myelodysplastic syndromes patients with IDH1 Mutation present in 2.52% of all myelodysplastic syndromes patients [4].

IDH1 Mutation is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain IDH1 Mutation and myelodysplastic syndromes as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

IDH1 is altered in 0.89% of non-small cell lung carcinoma patients with IDH1 Mutation present in 0.82% of all non-small cell lung carcinoma patients [4].

IDH1 Mutation is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 0 are open and 2 are closed. Of the trials that contain IDH1 Mutation and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (0 open) [5].

IDH1 is altered in 0.48% of pancreatic carcinoma patients with IDH1 Mutation present in 0.45% of all pancreatic carcinoma patients [4].

IDH1 Mutation is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain IDH1 Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

IDH1 is altered in 0.36% of ovarian carcinoma patients with IDH1 Mutation present in 0.22% of all ovarian carcinoma patients [4].

IDH1 Mutation is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain IDH1 Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 2 clinical trials for ependymoma, of which 2 are open and 0 are closed. Of the trials that contain IDH1 Mutation and ependymoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IDH1 is altered in 85.53% of mixed glioma patients with IDH1 Mutation present in 85.53% of all mixed glioma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for mixed glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and mixed glioma as inclusion criteria, 1 is phase 3 (1 open) [5].

IDH1 is altered in 82.22% of anaplastic oligodendroglioma patients with IDH1 Mutation present in 82.22% of all anaplastic oligodendroglioma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 is altered in 82.14% of oligoastrocytoma patients with IDH1 Mutation present in 82.14% of all oligoastrocytoma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for oligoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and oligoastrocytoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH1 is altered in 81.17% of oligodendroglioma patients with IDH1 Mutation present in 81.17% of all oligodendroglioma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and oligodendroglioma as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH1 is altered in 59.78% of diffuse astrocytoma patients with IDH1 Mutation present in 59.78% of all diffuse astrocytoma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for diffuse astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and diffuse astrocytoma as inclusion criteria, 1 is phase 3 (1 open) [5].

IDH1 is altered in 49.63% of low grade glioma patients with IDH1 Mutation present in 49.63% of all low grade glioma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and low grade glioma as inclusion criteria, 1 is phase 3 (1 open) [5].

IDH1 is altered in 41.98% of astrocytoma patients with IDH1 Mutation present in 41.98% of all astrocytoma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and astrocytoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH1 is altered in 26.4% of diffuse glioma patients with IDH1 Mutation present in 26.36% of all diffuse glioma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 is altered in 25.0% of atypical chronic myeloid leukemia, BCR-ABL1 negative patients with IDH1 Mutation present in 25.0% of all atypical chronic myeloid leukemia, BCR-ABL1 negative patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 is altered in 17.82% of high-grade glioma, NOS patients with IDH1 Mutation present in 17.82% of all high-grade glioma, NOS patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 is altered in 6.9% of myeloproliferative neoplasm, unclassifiable patients with IDH1 Mutation present in 6.9% of all myeloproliferative neoplasm, unclassifiable patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 is altered in 6.62% of leukemia patients with IDH1 Mutation present in 6.62% of all leukemia patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for leukemia, of which 0 are open and 1 is closed. Of the trial that contains IDH1 Mutation and leukemia as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH1 is altered in 3.5% of hematopoietic and lymphoid malignancy patients with IDH1 Mutation present in 3.48% of all hematopoietic and lymphoid malignancy patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 is altered in 3.01% of melanoma patients with IDH1 Mutation present in 2.98% of all melanoma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 Mutation and melanoma as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH1 is altered in 2.2% of medulloblastoma patients with IDH1 Mutation present in 2.2% of all medulloblastoma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 is altered in 1.98% of central nervous system embryonal neoplasm patients with IDH1 Mutation present in 1.98% of all central nervous system embryonal neoplasm patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for central nervous system embryonal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 is altered in 1.96% of diffuse midline glioma, H3 K27M-mutant patients with IDH1 Mutation present in 1.96% of all diffuse midline glioma, H3 K27M-mutant patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 is altered in 1.84% of essential thrombocythemia patients with IDH1 Mutation present in 1.84% of all essential thrombocythemia patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for essential thrombocythemia, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and essential thrombocythemia as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 is altered in 1.82% of primary brain neoplasm patients with IDH1 Mutation present in 1.82% of all primary brain neoplasm patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for primary brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and primary brain neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH1 is altered in 1.79% of myelofibrosis transformation in essential thrombocythemia patients with IDH1 Mutation present in 1.79% of all myelofibrosis transformation in essential thrombocythemia patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for myelofibrosis transformation in essential thrombocythemia, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 is altered in 1.77% of primary myelofibrosis patients with IDH1 Mutation present in 1.77% of all primary myelofibrosis patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and primary myelofibrosis as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 is altered in 1.6% of myelodysplastic syndrome with excess blasts-2 patients with IDH1 Mutation present in 1.6% of all myelodysplastic syndrome with excess blasts-2 patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 0 are open and 1 is closed. Of the trial that contains IDH1 Mutation and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (0 open) [5].

IDH1 is altered in 1.51% of myelofibrosis patients with IDH1 Mutation present in 1.51% of all myelofibrosis patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains IDH1 Mutation and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [5].

IDH1 is altered in 1.45% of schwannoma patients with IDH1 Mutation present in 1.45% of all schwannoma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and schwannoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH1 is altered in 1.39% of bladder carcinoma patients with IDH1 Mutation present in 1.22% of all bladder carcinoma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 Mutation and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH1 is altered in 1.3% of colorectal carcinoma patients with IDH1 Mutation present in 1.15% of all colorectal carcinoma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH1 is altered in 1.32% of sarcoma patients with IDH1 Mutation present in 1.09% of all sarcoma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 Mutation and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH1 is altered in 1.41% of gallbladder carcinoma patients with IDH1 Mutation present in 1.06% of all gallbladder carcinoma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 Mutation and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

IDH1 is altered in 1.02% of chronic myelomonocytic leukemia patients with IDH1 Mutation present in 1.02% of all chronic myelomonocytic leukemia patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

IDH1 is altered in 1.01% of myelodysplastic/myeloproliferative neoplasm patients with IDH1 Mutation present in 1.01% of all myelodysplastic/myeloproliferative neoplasm patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 is altered in 0.64% of prostate carcinoma patients with IDH1 Mutation present in 0.56% of all prostate carcinoma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH1 is altered in 0.52% of head and neck carcinoma patients with IDH1 Mutation present in 0.52% of all head and neck carcinoma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH1 is altered in 0.66% of gastric carcinoma patients with IDH1 Mutation present in 0.44% of all gastric carcinoma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH1 is altered in 0.4% of multiple myeloma patients with IDH1 Mutation present in 0.4% of all multiple myeloma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 Mutation and multiple myeloma as inclusion criteria, 1 is phase 2 (0 open) [5].

IDH1 is altered in 0.21% of gastrointestinal stromal tumor patients with IDH1 Mutation present in 0.21% of all gastrointestinal stromal tumor patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 0 are open and 1 is closed. Of the trial that contains IDH1 Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH1 is altered in 0.39% of pleural mesothelioma patients with IDH1 Mutation present in 0.2% of all pleural mesothelioma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 Mutation and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH1 is altered in 0.13% of clear cell renal cell carcinoma patients with IDH1 Mutation present in 0.13% of all clear cell renal cell carcinoma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 Mutation and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH1 is altered in 0.2% of renal cell carcinoma patients with IDH1 Mutation present in 0.07% of all renal cell carcinoma patients [4].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 Mutation and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for central nervous system ganglioneuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for central nervous system neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, non-WNT/non-SHH, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, SHH-activated, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and medulloblastoma, SHH-activated as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, WNT-activated, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for medulloepithelioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and meningioma as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 Mutation and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 Mutation and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 0 are open and 1 is closed. Of the trial that contains IDH1 Mutation and plasma cell leukemia as inclusion criteria, 1 is phase 2 (0 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and polycythemia vera as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for polycythemia vera, post-polycythemic myelofibrosis phase, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and polycythemia vera, post-polycythemic myelofibrosis phase as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH1 Mutation is an inclusion criterion in 1 clinical trial for primary central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 Mutation and primary central nervous system lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].